Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES.

AIMS The pattern of atrial fibrillation (AF) occurrence-paroxysmal, persistent, or permanent-is associated with progressive stages of atrial dysfunction and structural changes and may therefore be associated with progressively higher stroke risk. However, previous studies have not consistently shown AF pattern to predict stroke but have been hampered by methodological shortcomings of low power, variable event ascertainment, and variable anticoagulant use. METHODS AND RESULTS We analysed the rates of stroke and systemic embolism in 6563 aspirin-treated patients with AF from the ACTIVE-A/AVERROES databases. There was thorough searching for events and adjudication. Multivariable analyses were performed with the adjustment for known risk factors for stroke. Mean age of patients with paroxysmal, persistent, and permanent AF was 69.0 ± 9.9, 68.6 ± 10.2, and 71.9 ± 9.8 years (P < 0.001). The CHA2DS2-VASc score was similar in patients with paroxysmal and persistent AF (3.1 ± 1.4), but was higher in patients with permanent AF (3.6 ± 1.5, P < 0.001). Yearly ischaemic stroke rates were 2.1, 3.0, and 4.2% for paroxysmal, persistent, and permanent AF, respectively, with adjusted hazard ratio of 1.83 (P < 0.001) for permanent vs. paroxysmal and 1.44 (P = 0.02) for persistent vs. paroxysmal. Multivariable analysis identified age ≥ 75 year, sex, history of stroke or TIA, and AF pattern as independent predictors of stroke, with AF pattern being the second strongest predictor after prior stroke or TIA. CONCLUSION In a large population of non-anticoagulated AF patients, pattern of AF was a strong independent predictor of stroke risk and may be helpful to assess the risk/benefit for anticoagulant therapy, especially in lower risk patients.

[1]  Deepak K Gupta,et al.  Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48. , 2014, European heart journal.

[2]  P. Petersen,et al.  Embolic complications in paroxysmal atrial fibrillation. , 1986, Stroke.

[3]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[4]  W. Kannel,et al.  Epidemiologic features of chronic atrial fibrillation: the Framingham study. , 1982, The New England journal of medicine.

[5]  Martha J. Radford,et al.  Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation , 2001 .

[6]  Salim Yusuf,et al.  Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: results from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study. , 2012, Journal of the American College of Cardiology.

[7]  G. Lip,et al.  Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry , 2013, PloS one.

[8]  K. Flegel,et al.  Risk factors for stroke and other embolic events in patients with nonrheumatic atrial fibrillation. , 1989, Stroke.

[9]  Bernard Rosner,et al.  The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. , 1990, The New England journal of medicine.

[10]  L. Moroni,et al.  Thromboembolic event rate in paroxysmal and persistent atrial fibrillation: Data from the GISSI-AF trial , 2013, BMC Cardiovascular Disorders.

[11]  M. Aguilar,et al.  Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation , 2007, Annals of Internal Medicine.

[12]  Daniel Levy,et al.  Arrhythmias: abstractA risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community. The Framingham Heart Study☆ , 2003 .

[13]  L. Frison,et al.  Stroke event rates in anticoagulated patients with paroxysmal atrial fibrillation , 2008, Journal of internal medicine.

[14]  The efficacy of aspirin in patients with atrial fibrillation. Analysis of pooled data from 3 randomized trials. The Atrial Fibrillation Investigators. , 1997, Archives of internal medicine.

[15]  Independent predictors of stroke in patients with atrial fibrillation , 2007, Neurology.

[16]  R McBride,et al.  Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. , 1999, Stroke.

[17]  Alexander Parkhomenko,et al.  Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.

[18]  Jeroen J. Bax,et al.  Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[19]  S. Yusuf,et al.  Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy , 2012, Circulation.

[20]  F. Humar,et al.  Lone atrial fibrillation: prognostic differences between paroxysmal and chronic forms after 10 years of follow-up. , 1999, American heart journal.

[21]  G. Lip,et al.  Fibrinogen and fibrin D-dimer levels in paroxysmal atrial fibrillation: evidence for intermediate elevated levels of intravascular thrombogenesis. , 1996, American heart journal.

[22]  M. Rosenqvist,et al.  Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. , 2010, European heart journal.

[23]  J. Halperin,et al.  Subclinical atrial fibrillation and the risk of stroke. , 2012, The New England journal of medicine.

[24]  A. Banerjee,et al.  Pattern of atrial fibrillation and risk of outcomes: the Loire Valley Atrial Fibrillation Project. , 2012, International journal of cardiology.

[25]  D. Fatkin,et al.  Relations between left atrial appendage blood flow velocity, spontaneous echocardiographic contrast and thromboembolic risk in vivo. , 1994, Journal of the American College of Cardiology.

[26]  S. Yusuf,et al.  Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. , 2010, American heart journal.

[27]  Apixaban versus Warfarin in Patients with Atrial Fibrillation , 2012 .

[28]  Robby Nieuwlaat,et al.  Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. , 2010, Journal of the American College of Cardiology.

[29]  J. Le Heuzey,et al.  Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events. , 2006, American heart journal.

[30]  Leon Poller,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[31]  B. Gersh,et al.  Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. , 2013, European heart journal.

[32]  Denis Roy,et al.  Usefulness of anticoagulant therapy in the prevention of embolic complications of atrial fibrillation. , 1986, American heart journal.

[33]  Habib Gamra,et al.  Distribution and Risk Profile of Paroxysmal, Persistent, and Permanent Atrial Fibrillation in Routine Clinical Practice: Insight From the Real-Life Global Survey Evaluating Patients With Atrial Fibrillation International Registry , 2012, Circulation. Arrhythmia and electrophysiology.

[34]  M. Pathy,et al.  Atrial fibrillation and stroke in elderly hospitalized patients. , 1986, Age and ageing.

[35]  J. Halperin,et al.  Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. , 2000, Journal of the American College of Cardiology.

[36]  M. Wallander,et al.  Risk of cardiovascular and cerebrovascular events after atrial fibrillation diagnosis. , 2009, International journal of cardiology.

[37]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[38]  C. Granger,et al.  Biomarkers in atrial fibrillation: a clinical review. , 2013, European heart journal.

[39]  Gregory Y H Lip,et al.  Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.

[40]  Salim Yusuf,et al.  Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. , 2007, Journal of the American College of Cardiology.

[41]  P. Platonov,et al.  Structural abnormalities in atrial walls are associated with presence and persistency of atrial fibrillation but not with age. , 2011, Journal of the American College of Cardiology.

[42]  A. Capucci,et al.  Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation? , 2008, European heart journal.